PRL2 inhibition, therefore, provides a mechanism and potential therapeutic strategy to elevate the level of PTEN protein, attenuate hyperactivated AKT signaling, and rescue the AML phenotype. The gene discussed is PTEN; the disease is acute myeloid leukemia.